Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
34
SUPN Quote, Financials, Valuation and Earnings
Last price:
$45.07
Seasonality move
:
-0.27%
Day range:
$44.28 - $45.10
52-week range:
$29.16 - $57.65
Dividend yield:
0%
P/E ratio:
41.17x
P/S ratio:
3.70x
P/B ratio:
2.45x
Volume:
527.5K
Avg. volume:
998K
1-year change:
21.4%
Market cap:
$2.6B
Revenue:
$661.8M
EPS (TTM):
-$0.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$180.2M | $0.82 | 12.24% | 60.84% | $60.50 |
|
ASMB
Assembly Biosciences, Inc.
|
$7.5M | -$0.65 | 0.89% | -46.09% | $41.00 |
|
BBIO
BridgeBio Pharma, Inc.
|
$106.1M | -$0.78 | 2418.34% | -55.45% | $84.65 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.34% | -4.29% | $178.76 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$44.76 | $60.50 | $2.6B | 41.17x | $0.00 | 0% | 3.70x |
|
ASMB
Assembly Biosciences, Inc.
|
$35.27 | $41.00 | $557.9M | -- | $0.00 | 0% | 8.16x |
|
BBIO
BridgeBio Pharma, Inc.
|
$74.76 | $84.65 | $14.4B | -- | $0.00 | 0% | 40.25x |
|
BIIB
Biogen, Inc.
|
$181.98 | $178.76 | $26.7B | 16.60x | $0.00 | 0% | 2.75x |
|
CRMD
CorMedix, Inc.
|
$10.64 | $19.00 | $838.3M | 5.18x | $0.00 | 0% | 3.58x |
|
VKTX
Viking Therapeutics, Inc.
|
$35.41 | $93.39 | $4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
3.87% | 0.900 | 1.55% | 1.37x |
|
ASMB
Assembly Biosciences, Inc.
|
1.49% | 3.596 | 0.68% | 4.37x |
|
BBIO
BridgeBio Pharma, Inc.
|
350.59% | 0.711 | 27% | 3.52x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SUPN
Supernus Pharmaceuticals, Inc.
|
$148.3M | -$61M | -1.78% | -1.84% | -31.77% | -$61.8M |
|
ASMB
Assembly Biosciences, Inc.
|
$10.8M | -$10.9M | -64.14% | -67.09% | -100.87% | -$15.2M |
|
BBIO
BridgeBio Pharma, Inc.
|
$113.4M | -$136.4M | -109.98% | -- | -112.97% | -$112.4M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Supernus Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SUPN or ASMB?
Assembly Biosciences, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -85.24%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Assembly Biosciences, Inc.'s return on equity of -67.09%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B ASMBAssembly Biosciences, Inc.99.7% -$0.72 $185.5M -
What do Analysts Say About SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a consensus price target of $60.50, signalling upside risk potential of 35.17%. On the other hand Assembly Biosciences, Inc. has an analysts' consensus of $41.00 which suggests that it could grow by 16.25%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Assembly Biosciences, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Assembly Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 ASMBAssembly Biosciences, Inc.4 0 0 -
Is SUPN or ASMB More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Assembly Biosciences, Inc. has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.805%.
-
Which is a Better Dividend Stock SUPN or ASMB?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assembly Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Assembly Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or ASMB?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Assembly Biosciences, Inc. quarterly revenues of $10.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Assembly Biosciences, Inc.'s net income of -$9.2M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Assembly Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 3.70x versus 8.16x for Assembly Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.3.70x 41.17x $192.1M -$45.1M ASMBAssembly Biosciences, Inc.8.16x -- $10.8M -$9.2M
-
Which has Higher Returns SUPN or BBIO?
BridgeBio Pharma, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -153.22%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat BridgeBio Pharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B BBIOBridgeBio Pharma, Inc.93.98% -$0.95 $781.7M -
What do Analysts Say About SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a consensus price target of $60.50, signalling upside risk potential of 35.17%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $84.65 which suggests that it could grow by 13.23%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than BridgeBio Pharma, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than BridgeBio Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 BBIOBridgeBio Pharma, Inc.14 1 0 -
Is SUPN or BBIO More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.58%.
-
Which is a Better Dividend Stock SUPN or BBIO?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or BBIO?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than BridgeBio Pharma, Inc. quarterly revenues of $120.7M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than BridgeBio Pharma, Inc.'s net income of -$184.9M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 3.70x versus 40.25x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.3.70x 41.17x $192.1M -$45.1M BBIOBridgeBio Pharma, Inc.40.25x -- $120.7M -$184.9M
-
Which has Higher Returns SUPN or BIIB?
Biogen, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 19%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About SUPN or BIIB?
Supernus Pharmaceuticals, Inc. has a consensus price target of $60.50, signalling upside risk potential of 35.17%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.77%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 BIIBBiogen, Inc.14 19 0 -
Is SUPN or BIIB More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock SUPN or BIIB?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or BIIB?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Biogen, Inc.'s PE ratio is 16.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 3.70x versus 2.75x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.3.70x 41.17x $192.1M -$45.1M BIIBBiogen, Inc.2.75x 16.60x $2.5B $466.5M
-
Which has Higher Returns SUPN or CRMD?
CorMedix, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 49.9%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About SUPN or CRMD?
Supernus Pharmaceuticals, Inc. has a consensus price target of $60.50, signalling upside risk potential of 35.17%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that CorMedix, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 CRMDCorMedix, Inc.4 0 0 -
Is SUPN or CRMD More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock SUPN or CRMD?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or CRMD?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 3.70x versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.3.70x 41.17x $192.1M -$45.1M CRMDCorMedix, Inc.3.58x 5.18x $104.3M $108.6M
-
Which has Higher Returns SUPN or VKTX?
Viking Therapeutics, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of --. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital SUPNSupernus Pharmaceuticals, Inc.77.21% -$0.80 $1.1B VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a consensus price target of $60.50, signalling upside risk potential of 35.17%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Viking Therapeutics, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Supernus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SUPNSupernus Pharmaceuticals, Inc.4 1 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is SUPN or VKTX More Risky?
Supernus Pharmaceuticals, Inc. has a beta of 0.715, which suggesting that the stock is 28.462% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock SUPN or VKTX?
Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SUPN or VKTX?
Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 3.70x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SUPNSupernus Pharmaceuticals, Inc.3.70x 41.17x $192.1M -$45.1M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
